Table 1. In Vitro Cytotoxic Activity of the Designed Compounds.

	IC50 (μM)a
comp. no	HePG2b	HCT-116c	MCF-7d	HeLae
CA-4f	4.50 ± 0.2	5.23 ± 0.3	4.17 ± 0.2	5.57 ± 0.3
4	62.57 ± 3.1	69.03 ± 3.5	62.91 ± 3.1	76.92 ± 3.8
5a	22.03 ± 1.1	29.36 ± 1.5	30.00 ± 1.5	50.86 ± 2.5
5b	10.92 ± 0.5	24.38 ± 1.2	22.80 ± 1.1	28.30 ± 1.4
5c	11.87 ± 0.6	12.88 ± 0.6	15.49 ± 0.8	16.02 ± 0.8
6a	8.17 ± 0.4	28.94 ± 1.4	40.87 ± 2.0	47.74 ± 2.4
6b	74.61 ± 3.7	83.68 ± 4.2	65.27 ± 3.3	87.32 ± 4.4
6c	33.86 ± 1.7	37.18 ± 1.9	41.36 ± 2.1	48.19 ± 2.4
6d	4.03 ± 0.2	15.74 ± 0.8	9.64 ± 0.5	18.69 ± 0.9
6e	19.76 ± 1.0	18.03 ± 0.9	39.08 ± 2.0	58.84 ± 2.9
7a	94.13 ± 4.7	52.48 ± 2.6	>100	54.09 ± 2.7
7b	34.17 ± 1.7	9.35 ± 0.5	44.84 ± 2.2	13.12 ± 0.7
7c	6.26 ± 0.3	7.30 ± 0.4	10.01 ± 0.5	9.85 ± 0.5
7d	28.10 ± 1.4	33.10 ± 1.7	41.42 ± 2.1	29.78 ± 1.5
7e	25.65 ± 1.3	31.15 ± 1.6	34.98 ± 1.7	41.45 ± 2.1
8	3.35 ± 0.2	5.32 ± 0.3	8.66 ± 0.4	6.15 ± 0.3
9a	7.32 ± 0.4	10.13 ± 0.5	9.80 ± 0.5	10.59 ± 0.5
9b	8.04 ± 0.4	9.93 ± 0.5	11.55 ± 0.6	13.42 ± 0.7
10	49.62 ± 2.5	55.30 ± 2.8	60.62 ± 3.0	48.03 ± 2.4
11	92.97 ± 4.6	86.69 ± 4.3	95.77 ± 4.8	89.86 ± 4.5
12	>100	88.46 ± 4.4	>100	91.82 ± 4.6
13a	14.17 ± 0.7	20.08 ± 1.0	16.95 ± 0.8	32.39 ± 1.6
13b	25.67 ± 1.3	27.42 ± 1.4	32.03 ± 1.6	43.93 ± 2.2

^aIC₅₀ (μM): expressed as mean ± SD 1–10 (very strong); 11–20 (strong); 21–50 (moderate); 51–100 (weak); and above 100 (noncytotoxic).

^bHuman hepatocellular carcinoma cell line (HepG2).

^cHuman breast adenocarcinoma cell line (MCF-7).

^dHuman colorectal carcinoma cell line (HCT-116).

^eEpitheloid cervix carcinoma cell line (HeLa).

^fCA-4: combretastatin A-4.